Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Gorilla Technology
GRRR
5
Palantir
PLTR
(FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Net premium income has been realized | 1.61%101.36B | ---- | 6.85%51.78B | ---- | 11.80%99.76B | ---- | 16.39%48.47B | ---- | -38.06%89.23B | ---- |
-Net premium income | 1.61%101.36B | ---- | 6.85%51.78B | ---- | 11.80%99.76B | ---- | 16.39%48.47B | ---- | -39.61%89.23B | ---- |
-Including:Total premium income | 1.61%101.36B | 0.43%146.07B | 6.85%51.78B | -13.82%50.09B | 11.80%99.76B | 10.53%145.44B | 16.39%48.47B | 21.57%58.12B | -45.17%89.23B | --131.59B |
Investment income | 633.60%6.83B | ---- | 939.65%3.82B | ---- | 68.99%-1.28B | ---- | 72.20%-455.05M | ---- | -127.97%-4.13B | ---- |
Banking income | 1.15%9.23B | ---- | 2.84%4.54B | ---- | -0.14%9.13B | ---- | -3.72%4.42B | ---- | --9.14B | ---- |
Exchange gains | -150.74%-341.76M | ---- | -101.72%-25.88M | ---- | -49.84%673.59M | ---- | 59.65%1.51B | ---- | 5,669.44%1.34B | ---- |
Special items of income | -6.44%1.04B | ---- | -0.21%563.45M | ---- | 32.31%1.12B | ---- | 53.96%564.61M | ---- | -73.74%843.92M | ---- |
Total income | 7.99%118.13B | 11.35%60.69B | 13.45%109.39B | 18.73%54.5B | -41.19%96.42B | |||||
Insurance business expenses and other expenses | -1.22%-106.31B | ---- | -1.89%-54.35B | ---- | -9.03%-105.03B | ---- | -15.04%-53.34B | ---- | -134.68%-96.33B | ---- |
-Financial expenses - expenses | 13.58%-2.01B | ---- | 6.91%-1.03B | ---- | -20.16%-2.32B | ---- | -7.40%-1.1B | ---- | 5.74%-1.93B | ---- |
-Special items of operating payout | -324.13%-4.63B | ---- | -289.04%-1.53B | ---- | 50.16%-1.09B | ---- | 70.80%-392.3M | ---- | 87.02%-2.19B | ---- |
Total payment、 claims and expenses | -1.22%-106.31B | -1.89%-54.35B | -9.03%-105.03B | -15.04%-53.34B | 39.24%-96.33B | |||||
Operating profit | 170.76%11.82B | 445.56%6.34B | 4,583.85%4.37B | 350.40%1.16B | -98.28%93.2M | |||||
Attributable share of joint ventures and joint ventures | 0.94%1.98B | ---- | -10.21%1.08B | ---- | 234.08%1.96B | ---- | 99.65%1.2B | ---- | -186.67%-1.46B | ---- |
Earning before tax | 118.14%13.8B | 214.00%7.41B | 562.24%6.33B | 1,623.69%2.36B | -119.25%-1.37B | |||||
Tax | -408.25%-2.72B | ---- | -407.50%-1.49B | ---- | -208.44%-534.69M | ---- | -228.40%-294.03M | ---- | 140.63%493.05M | ---- |
After-tax profit from continuing operations | 91.35%11.08B | 186.47%5.92B | 761.52%5.79B | 464.81%2.07B | -114.85%-875.35M | |||||
Earning After tax | 91.35%11.08B | 17.85%6.19B | 186.47%5.92B | 11.26%1.37B | 761.52%5.79B | 93.23%5.25B | 464.81%2.07B | 166.74%1.24B | -114.85%-875.35M | 2.72B |
Minority profit | 278.91%523.45M | ---- | 251.77%194.78M | ---- | 125.09%138.15M | ---- | 155.22%55.37M | ---- | -828.86%-550.7M | ---- |
Profits attributable to shareholders | 86.77%10.56B | 184.68%5.73B | 1,841.12%5.65B | 331.46%2.01B | -105.45%-324.65M | |||||
Basic earnings per share | 92.31%0.25 | 160.00%0.13 | 1,400.00%0.13 | 400.00%0.05 | -107.14%-0.01 | |||||
Diluted earnings per share | 92.31%0.25 | 160.00%0.13 | 750.00%0.13 | 1,766.67%0.05 | -115.38%-0.02 | |||||
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | IAS | CAS (2007) | IAS | CAS (2007) | IAS | CAS (2007) | IAS | CAS (2007) | IAS | CAS (2007) |
Audit Opinions | Unqualified Opinion | -- | -- | -- | Unqualified Opinion | -- | -- | -- | Unqualified Opinion | -- |
Auditor | KPMG Huazhen (Special General Partnership), KPMG | -- | -- | -- | PricewaterhouseCoopers, PricewaterhouseCoopers Zhongtian | -- | -- | -- | PricewaterhouseCoopers, PricewaterhouseCoopers Zhongtian | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.